Once-daily oral trovafloxacin in the treatment of diabetic foot infections - Results of an open-label, noncomparative, multicentre trial

被引：8

作者：

Daniel, R ^{[1
]}

机构：

[1] Pfizer Ltd, Cent Res, Sandwich CT13 9NJ, Kent, England

来源：

DRUGS | 1999年 / 58卷 / Suppl 2期

关键词：

D O I：

10.2165/00003495-199958002-00097

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：291 / 292

页数：2

共 6 条

[1] In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates [J].

Felmingham, D ;

Robbins, MJ ;

Ingley, K ;

Mathias, I ;

Bhogal, H ;

Leakey, A ;

Ridgway, GL ;

Gruneberg, RN .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :43-49

[2] Susceptibility of anaerobic bacteria to trovafloxacin: Comparison with other quinolones and non-quinolone antibiotics [J].

Spangler, SK ;

Jacobs, MR ;

Appelbaum, PC .

INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 :S101-S109

[3]

TAYLOR A, 1997, P 37 INT C ANT AG A, V66, P14

[4] PHARMACOKINETICS AND SAFETY OF TROVAFLOXACIN (CP-99,219), A NEW QUINOLONE ANTIBIOTIC, FOLLOWING ADMINISTRATION OF SINGLE ORAL DOSES TO HEALTHY MALE-VOLUNTEERS [J].

TENG, RL ;

HARRIS, SC ;

NIX, DE ;

SCHENTAG, JJ ;

FOULDS, G ;

LISTON, TE .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (02) :385-394

[5]

VINCENT J, 1996, P 36 INT C ANT AG A, V6, P2

[6]

[No title captured]

← 1 →